Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy

Xinfu XIE; Bingying XIE; Quan ZHENG; Lixia XU; Xinling LIANG; Zhiming YE

doi:10.16016/j.1000-5404.202012213

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy

Clinical Medicine | 更新时间：2026-01-09

- Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy
- Journal of Third Military Medical University Vol. 43, Issue 12, Pages: 1173-1178(2021)
- 作者机构：
  
  1.510515 广州南方医科大学第二临床医学院
  2.510000 广州, 广东省人民医院(广东省医学科学院)肾内科
  3.515063 广东汕头, 汕头大学医学院
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.202012213
  CLC： R451;R692;R969.4
- Received：26 December 2020，
  
  Revised：2021-02-06，
  
  Published：30 June 2021
- 稿件说明：
移动端阅览
Xinfu XIE, Bingying XIE, Quan ZHENG, et al. Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy[J]. Journal of Third Military Medical University, 2021, 43(12): 1173-1178.
DOI：

Xinfu XIE, Bingying XIE, Quan ZHENG, et al. Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy[J]. Journal of Third Military Medical University, 2021, 43(12): 1173-1178. DOI： 10.16016/j.1000-5404.202012213.

摘要

目的

评价环磷酰胺(cyclophosphamide

CTX)静脉冲击联合糖皮质激素在治疗特发性膜性肾病(idiopathic membranous nephropathy，IMN)治疗中的有效性和安全性。

方法

回顾性分析78例临床表现为肾病综合征(nephrotic syndrome

NS)的IMN患者临床资料。治疗组: 静脉滴注CTX联合糖皮质激素组39例；对照组: 口服CTX联合糖皮质激素组39例。比较两组患者治疗前及治疗后3、6、12个月的蛋白尿缓解、血清白蛋白、估算肾小球滤过率(estimated glomerular filtration rate，eGFR)变化、复发率及不良反应发生情况。

结果

ICTX组在3、6、12个月的蛋白尿总缓解率高于OCTX组，分别为50.0%

46.4%，59.4%

50.0%，88.9%

75%，但差异无统计学意义。两组患者在治疗3、6、12个月后血清白蛋白(sALB)、eGFR较基线值均明显升高，治疗3个月时，ICTX组sALB升高更显著(6.2

4.8 g/L，

=0.013)。两组治疗后24 h尿蛋白(24 h UP)、血清肌酐(Scr)基线值均明显下降(

0.05)。在完全缓解(complete remission，CR)或部分缓解(partial remission，PR)后，ICTX组和OCTX组复发率分别为8.3%和13%，但差异无统计学意义。治疗3个月时，ICTX组血WBC较OCTX组高。ICTX组共发生9例(23.1%)不良反应，而OCTX组为10例(25.6%)。

结论

ICTX组方案可显著降低临床表现为NS的IMN患者尿蛋白，提高蛋白尿缓解率，且治疗结束后复发率低，同时可更快速升高血清白蛋白，耐受性好，不良反应无明显增加。

Abstract

Objective

To evaluate the efficacy and safety of high-dose cyclophosphamide (CTX) intravenous injection combined with glucocorticoid in the treatment of idiopathic membranous nephropathy (IMN).

Methods

Clinical data of 78 IMN patients with manifestation of nephrotic syndrome (NS) admitted in Guangdong Provincial People's Hospital from January 2007 to June 2019 were collected and retrospectively analyzed. The patients were assigned into either intravenous CTX combined with glucocorticoid group (ICTX group

n=39)

or oral CTX combined with glucocorticoid group (OCTX group

n=39). The subjects of ICTX group were treated with monthly intravenous CTX administration 0.50~0.75 g/m

+oral prednisone 0.5 mg/(kg·d) for 6 months. By contrast

those in OCTX group were given intravenous methylprednisolone 0.5 g qd×3 d+oral prednisone 0.5 mg/(kg·d)×27 d in the firs

third and fifth month

respectively

and given oral CTX 2.5mg/(kg·d)+ oral prednisone 10 mg/d in the second

fourth and sixth month

respectively. Comparison was made between the 2 groups about the remission of proteinuria

serum albumin (sALB)

estimated glomerular filtration rate (eGFR)

recurrence rate and incidence of adverse reactions (ADR) before and 3

6 and 12 months after the treatment.

Results

The total remission rate of proteinuria in ICTX group was higher than that in OCTX group at 3

12 months (50.0%

46.4%; 59.4%

50.0%; 88.9%

75.0%

respectively)

though showed no significant differences. sALB and eGFR in both groups were significantly increased from baseline

while 24 h urinary protein (24hUP) and serum creatinine (Scr) were decreased in 3

12 months after the treatment (

0.05); and sALB had a more significant rise in ICTX group than OCTX group at 3 months (6.2

4.8 g/L

=0.013). After complete remission (CR) or partial remission (PR)

the recurrence rates of ICTX and OCTX groups represented 8.3% and 13.0%

respectively

with no significant differences. In addition

the WBC count in the ICTX group was higher than that in the OCTX group at 3 months. Finally

a total of 9 cases of ADR occurred in the ICTX group (23.1%) and 10 cases in the OCTX group (25.6%).

Conclusion

The ICTX regimen significantly reduces proteinuria of IMN patients with clinical manifestation of NS

improving the remission rate of proteinuria

increasing serum albumin rapidly

and showing a low recurrence rate

good tolerance

as well as no significant increase in adverse reactions.

关键词

Keywords

references

BOMBACK A S, FERVENZA F C. Membranous nephropathy: approaches to treatment[J]. Am J Nephrol, 2018, 47(Suppl 1): 30-42. DOI: 10.1159/000481635.

GUO W, ZHANG Y, GAO C, et al . Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody[J ] . Peer J, 2020, 8: e8650. DOI: 10.7717/peerj.8650.

DAHAN K, DEBIEC H, PLAISIER E, et al . Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up[J ] . J Am Soc Nephrol, 2017, 28(1): 348-358. DOI: 10.1681/asn.2016040449.

胡晓帆, 徐静, 陈楠. 利妥昔单抗治疗特发性膜性肾病的进展[J]. 中华内科杂志, 2016, 55(7): 558-560.

HU X F, XU J, CHEN N. Progress of rituximab in the treatment of idiopathic membranous nephropathy[J]. Chin J Intern Med, 2016, 55(7): 558-560.

XU X, WANG G, CHEN N, et al . Long-term exposure to air pollution and increased risk of membranous nephropathy in China[J ] . J Am Soc Nephrol, 2016, 27(12): 3739-3746. DOI: 10.1681/asn.2016010093.

Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care[J]. Lancet 2015; 385(9981): 1983-1992. DOI: 10.1016/S0140-6736(15)60731-0.

NIKOLOPOULOU A, CONDON M, TURNER-STOKES T, et al . Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial[J ] . BMC Nephrol, 2019, 20(1): 352. DOI: 10.1186/s12882-019-1539-z.

KERI K C, BLUMENTHAL S, KULKARNI V, et al . Primary membranous nephropathy: comprehensive review and historical perspective[J ] . Postgrad Med J, 2019, 95(1119): 23-31. DOI: 10.1136/postgradmedj-2018-135729.

Group KDIGO. KDIGO clinical practice guideline for glomerulonephritis[J]. Kidney Int Suppl. 2012;2(2): 186-197.

LIANG Q, LI H, XIE X, et al . The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy[J ] . Ren Fail, 2017, 39(1): 512-518. DOI: 10.1080/0886022x.2017.1325371.

JHA V, GANGULI A, SAHA T K, et al . A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy[J ] . J Am Soc Nephrol , 2007, 18(6): 1899-1904. DOI: 10.1681/asn.2007020166.

HOWMAN A, CHAPMAN T L, LANGDON M M, et al . Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial[J ] . Lancet, 2013, 381(9868): 744-751. DOI: 10.1016/s0140-6736(12)61566-9.

VAN DE LOGT A E, HOFSTRA J M, WETZELS J F. Pharmacological treatment of primary membranous nephropathy in 2016[J]. Expert Rev Clin Pharmacol, 2016, 9(11): 1463-1478. DOI: 10.1080/17512433.2016.1225497.

FLOEGE J, BARBOUR S J, CATTRAN D C, et al . Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J ] . Kidney Int, 2019, 95(2): 268-280. DOI: 10.1016/j.kint.2018.10.018.

PONTICELLI C, ZUCCHELLI P, IMBASCIATI E, et al . Controlled trial of monthly alternated courses of steroid and chlorambucil for idiopathic membranous nephropathy[J ] . Proc Eur Dial Transpl Assoc Eur Dial Transpl Assoc, 1983, 19: 717-723.

REN S, WANG Y, WANG Y, et al . Comparative effectiveness and tolerance of immunosuppressive treatm ents for idiopathic membranous nephropathy: a network meta-analysis[J ] . PLoS ONE, 2017, 12(9): e0184398. DOI: 10.1371/journal.pone.0184398.

LI Y C, HUANG J, LI X, et al . A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: a meta-analysis[J ] . Nefrologia, 2019, 39(3): 269-276. DOI: 10.1016/j.nefro.2018.10.008.

POZDZIK A, BROCHÉRIOU I, DAVID C, et al . Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management[J ] . Biomed Res Int, 2018, 2018: 6281054. DOI: 10.1155/2018/6281054.

Mathrani V, Alejmi A, Griffin S, et al . Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy[J ] . Clin Kidney J. 2017;10(4): 450-454. DOI: 10.1093/ckj/sfw152.

RAMACHANDRAN R, HN H K, KUMAR V, et al . Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial[J ] . Nephrology (Carlton), 2016, 21(2): 139-146. DOI: 10.1111/nep.12569.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy of different doses of methylprednisolone on AECOPD mice induced by influenza A virus infection

Efficacy and prognosis of glucocorticoid therapy for septic shock: a meta analysis

Glucocorticoids and high pressure oxygen in prevention and treatment of delayed encephalopathy after acute carbon monoxide poisoning: a meta-analysis for efficacy and safety

Therapeutic effect of amitriptyline on phenotype-induced interstitial cystitis in rats

Expression of glucocorticoid receptor in HaCaT cells under dexamethasone treatment or after withdrawal

Related Author

GUI Rui

ZENG Qiang

LI Wu

LIANG Cheng

ZHOU Weijia

DAI Xiaotian

DENG Guohong

XIONG Wei

Related Institution

Department of Geriatrics and Special Medical Services

Department of Infectious Diseases

Department of Respiratory and Critical Care Medicine， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Yu-Yue Pathology Scientific Research Center

Department of Emergency, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University

⁰